Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (261-270 of 279) with videos related to

Pageof 28
Sort By:
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Nature Medicine|June 19, 2019
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
International Journal of Cancer|January 31, 2024
A prediction model for response to immune checkpoint inhibition in advanced melanomaIsabella A J van Duin, Rik J Verheijden, Paul J van Diest, et al.
Nature Communications|December 23, 2021
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinomaJoris L Vos, Joris B W Elbers, Oscar Krijgsman, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2021
Adjuvant treatment for melanoma in clinical practice - Trial versus realityMelissa M de Meza, Rawa K Ismail, Daan Rauwerdink, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Medicine|September 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 28

Showing results (261-270 of 279) with videos related to

Sort By:
Pageof 28
Nature Medicine|May 16, 2019
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
Nature Medicine|June 19, 2019
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trialLeonie Voorwerk, Maarten Slagter, Hugo M Horlings, et al.
International Journal of Cancer|January 31, 2024
A prediction model for response to immune checkpoint inhibition in advanced melanomaIsabella A J van Duin, Rik J Verheijden, Paul J van Diest, et al.
Nature Communications|December 23, 2021
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinomaJoris L Vos, Joris B W Elbers, Oscar Krijgsman, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2021
Adjuvant treatment for melanoma in clinical practice - Trial versus realityMelissa M de Meza, Rawa K Ismail, Daan Rauwerdink, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Medicine|September 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 28